Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Prader-Willi Syndrome

• Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
• An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
• Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
• Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
• Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
• A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
• A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
• Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
• Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome
• Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
• A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
• A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome
• Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
• Global Growth Hormone Study in Adults With Prader-Willi Syndrome
• Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
• An Open-Label Study of DCCR Tablet in Patients With PWS
• Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome
• CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
• Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
• Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
• Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
• GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
• A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome
• A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
• A Study of GLWL-01 in Patients With Prader-Willi Syndrome
• Intranasal Oxytocin for Infants With Prader-Willi Syndrome
• Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
• Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)
• Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years
• Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.
• A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
• Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome
• Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks
• Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome
• Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
• Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
• Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome
• Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell
• Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
• Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
• Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
• Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
• Oxytocin Trial in Prader-Willi Syndrome
• Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
• An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
• Ghrelin Suppression by Octreotide in Prader-Willi
• Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies
• Liraglutide Use in Prader-Willi Syndrome
• Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome
• Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
• Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
• Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?
• Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
• Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
• Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome
• Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
• Growth Hormone Use in Adults With Prader-Willi Syndrome
• Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
• Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
• Prader-Willi Syndrome and Appetite
• Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome